OTLK
NasdaqOUTLOOK THERAPEUTICS, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-09-30
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$3.0M
2016
$3.8M
2017
$3.1M
2018
$8.1M
2019
$1.4M
2025
Snapshot
SEC EDGAR · FY 2025-09-30Revenue$1.4M
Net Income$-62.4M
Gross Profit$57,205
Oper Income$-67.1M
EPS (dil)$-1.79
Rev/sh$0.01
FCF/sh$-0.43
Book/sh$-0.27
Gross M4.0%
Oper M-4744.3%
Profit M-4416.2%
FCF M-3697.6%
ROE193.9%
ROA-335.9%
ROIC-4.9%
R&D/Rev1922.9%
Rev Y/Y-82.6%
Rev 3Y CAGR-28.2%
EPS Y/Y55.9%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+87.6%
Current Ratio0.38
Quick Ratio0.31
Debt/Eq-43.16
Int Coverage-21.2×
Net Debt$1.4B
Total Debt$1.4B
Cash & Eq$8.1M
Total Assets$18.6M
Oper CF$-51.8M
Capex$437,307
Free CF$-52.3M
Buybacks—
Equity$-32.2M
Liabilities$50.8M
Shs Outstand0.12B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $3.8M | $3.1M | $8.1M | $1.4M |
| Gross Profit | — | — | — | — | $57,205 |
| Operating Income | $-51.3M | $-35.9M | $-29.6M | $-36.3M | $-67.1M |
| Net Income | $-53.3M | $-38.8M | $-30.1M | $-34.5M | $-62.4M |
| Diluted EPS | $-3.67 | $-1.80 | $-9.74 | $-1.98 | $-1.79 |
| Operating Cash Flow | $-45.5M | $-15.5M | $-33.0M | $-32.3M | $-51.8M |
| Free Cash Flow | $-46.6M | $-15.8M | $-35.8M | $-32.7M | — |
COMMUNITY · $OTLK0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.